ArticleBreast cancer research : BCR2020

KLF4 defines the efficacy of the epidermal growth factor receptor inhibitor, erlotinib, in triple-negative breast cancer cells by repressing the EGFR gene.

Melyssa S Roberts et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.